{"protocolSection": {"identificationModule": {"nctId": "NCT01912872", "orgStudyIdInfo": {"id": "CIGE025AMX02"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma", "officialTitle": "Multicentric, Open-label, Randomized, Parallel--group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12- Month Period, in Patients With Severe IgE-mediated Asthma Inadequately Controlled With High Doses of Corticosteroids.", "acronym": "MEXIC"}, "statusModule": {"statusVerifiedDate": "2019-06", "overallStatus": "TERMINATED", "whyStopped": "Termination was due to identified errors in data management handling after an internal audit by the sponsor performed by third party.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-11-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-08-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-01-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-07-29", "studyFirstSubmitQcDate": "2013-07-30", "studyFirstPostDateStruct": {"date": "2013-07-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-05-31", "resultsFirstSubmitQcDate": "2019-06-24", "resultsFirstPostDateStruct": {"date": "2019-07-02", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-06-24", "lastUpdatePostDateStruct": {"date": "2019-07-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Assess efficacy and safety of omalizumab treatment during 12 months in order to reduce the use of inhaled corticosteroid (ICS) in pediatric and adult participants with severe Immunoglobulin E (IgE)-mediated asthma inadequately controlled with high doses of corticosteroids.", "detailedDescription": "This was a multicentric, open label, randomized, parallel-group study with a 12-month treatment period. Participants were assigned to one of the 2 treatment groups, omalizumab plus budesonide/formoterol or budesonide/formoterol alone.\n\nThe study comprised 4 phases:\n\nDuring the 4-week run-in phase adult participants received budesonide 800 mg and formoterol 24 mg. If a participant complied with all inclusion and exclusion criteria and had received the according-to-age run-in proposed doses during the last month, the participant continued to the stable-steroid phase.\n\nDuring the 16-week stable-steroid phase, adult and pediatric eligible participants were randomized to one of the two treatment groups.\n\nDuring the 8-week steroid-reduction phase, adult and pediatric participants reduced 25% of the budesonide baseline dose every 2 weeks, depending of the asthma control, until they reached a 100% reduction of the baseline dose. The clinical control of asthma was defined according to criteria (GINA 2012)."}, "conditionsModule": {"conditions": ["Severe IgE-mediated Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 112, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omalizumab + budesonide and formoterol", "type": "EXPERIMENTAL", "description": "Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.", "interventionNames": ["Drug: Omalizumab", "Drug: Budesonide", "Drug: Formoterol"]}, {"label": "Budesonide and formoterol", "type": "ACTIVE_COMPARATOR", "description": "Participants will receive budesonide and formoterol according to maximum daily dose.", "interventionNames": ["Drug: Budesonide", "Drug: Formoterol"]}], "interventions": [{"type": "DRUG", "name": "Omalizumab", "description": "Subcutaneous injection dose according to the IgE level and body weight.", "armGroupLabels": ["Omalizumab + budesonide and formoterol"]}, {"type": "DRUG", "name": "Budesonide", "description": "Budesonide (400 \u03bcg, 200 \u03bcg or 100 \u03bcg) tablets taken orally according to maximum daily dose.", "armGroupLabels": ["Budesonide and formoterol", "Omalizumab + budesonide and formoterol"]}, {"type": "DRUG", "name": "Formoterol", "description": "Formoterol 12ug tablets taken orally according to maximum daily dose.", "armGroupLabels": ["Budesonide and formoterol", "Omalizumab + budesonide and formoterol"]}, {"type": "DRUG", "name": "Budesonide", "description": "Budesonide (400 \u03bcg, 200 \u03bcg or 100 \u03bcg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.", "armGroupLabels": ["Budesonide and formoterol", "Omalizumab + budesonide and formoterol"]}, {"type": "DRUG", "name": "Formoterol", "description": "Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.", "armGroupLabels": ["Budesonide and formoterol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Mean Prescribed Budesonide Dose (\u03bcg) at Baseline", "description": "prescribed budesonide dose (in \u03bcg) at Baseline in intention to treat population and in intention to treat population", "timeFrame": "Baseline"}], "secondaryOutcomes": [{"measure": "Number of Hospital Admissions Due to Asthma Exacerbation", "description": "A hospital admission is defined as admissions to hospital involving a stay of at least 24 hours.", "timeFrame": "12 month treatment duration"}, {"measure": "Days Missed in School/Work Due to Asthma Exacerbation Episodes", "description": "Participants /parent/legal guarding reported number of missed days of school or work at each study visit via diaries.", "timeFrame": "12 month treatment duration"}, {"measure": "Control of Asthma Symptoms- Daytime Symptoms", "description": "The clinical control of asthma was defined according to the following criteria (GINA 2012): 1-Daytime symptoms: none or less than twice a week 2-Limitations of daily activities: none 3-Nocturnal symptoms or awakening because of asthma: none 4-Need of relief or rescue medication: none or less than twice a week 5-Lung function (PEF or FEV1) without administration of bronchodilator: normal", "timeFrame": "12 month treatment duration"}, {"measure": "Control of Asthma Symptoms", "description": "The clinical control of asthma was defined according to the following criteria (GINA 2012): 1-Daytime symptoms: none or less than twice a week 2-Limitations of daily activities: none 3-Nocturnal symptoms or awakening because of asthma: none 4-Need of relief or rescue medication: none or less than twice a week 5-Lung function (PEF or FEV1) without administration of bronchodilator: normal", "timeFrame": "12 month treatment duration"}, {"measure": "Control of Asthma Symptoms- Rescue Medication Use", "description": "The clinical control of asthma was defined according to the following criteria (GINA 2012): 1-Daytime symptoms: none or less than twice a week 2-Limitations of daily activities: none 3-Nocturnal symptoms or awakening because of asthma: none 4-Need of relief or rescue medication: none or less than twice a week 5-Lung function (PEF or FEV1) without administration of bronchodilator: normal", "timeFrame": "12 month treatment duration"}, {"measure": "Participants Requiring Oral Systemic Corticosteroids During the 12 Month Study Duration", "description": "Number of days of concomitant medications use reported by participants at all visits via diaries.", "timeFrame": "12 month treatment duration"}, {"measure": "Asthma Control Questionnaire (ACQ) at Baseline", "description": "The Asthma Control Questionnaire (ACQ) has six questions to be answered by the participants, each with a 7 point scale (0-good control, 6-poor control), and one question where the actual pre-bronchodilator Forced expiratory volume in 1 second (FEV1) value expressed in % of predicted FEV1 was classified to scores from 0 (\\> 95% of predicted) to 6 (\\< 50% of predicted). The overall score is the average of the 7 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma.", "timeFrame": "Baseline"}, {"measure": "Asthma Quality of Life Questionnaire (AQLQ) at Baseline", "description": "The quality of life will be measured by the standardized version of the Asthma Quality of Life Questionnaire (AQLQ\\[S\\]) score for adults and the pediatric version of the AQLQ(S) for pediatric participants (PAQLQ\\[S\\]) . The AQLQ(S) and PAQLQ(S0 contain 4 domains (activity limitations, symptoms, emotional function, and environmental stimuli), with a total of 32 items; each item is measured in a 7-point Likert scale of 1 to 7 (1 = severe impairment, 7 = no impairment). All items are weighted equally. Mean score is calculated across all items within each domain and the overall score is the mean score of the 32 items.", "timeFrame": "Baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* Male and female between 6 and 55 years old. If female, participant of childbearing potential must use a safe and efficacious birth control method.\n* Asthma is considered as not well-controlled if participant has 3 or more of the following conditions:\n\n  1. Persistent day symptoms with current therapy twice at week or more, (siblings, dyspnea, cough, chest pain, thoracic oppression).\n  2. One or more night-time awakenings over the last 4 weeks.\n  3. Any limitation of age-appropriated habitual activities.\n  4. Need of rescue medication (short acting \u03b22 agonist) for two or more occasions per week during the last 4 weeks before screening and 2 consecutive weeks within the 4 weeks before selection.\n  5. Peak expiratory flow (PEF) or VEF1 \\<80% predicted or personal best (if known) this is not mandatory for pediatric participants (under 18 years old).\n* Despite continuous treatment with high-dose inhaled corticosteroids (ICS) or oral corticosteroids (OCS) (CSO\u2265 1 mg/kg/day) with or without controllers (As per GINA 2012 definition), the subject is receiving high doses of ICS (budesonide or its equivalent) and a long-acting \u03b22-agonists(LABA) (formoterol) for the past 12 weeks at visit 0.\n* At last one documented asthma exacerbation (defined as increase asthma symptoms requiring systemic corticosteroid rescue therapy) that requires visits to the emergency room or to be hospitalized in the past 12 months. It is also considered asthma exacerbation a non-planned visit that required rescue medication (\u03b22-agonists and/or steroid nebulization every 20 minutes or \u03b22-agonists inhaler shots every 20 minutes).\n* Positive skin test or in vitro reactivity to a perennial aeroallergen, documented during the 12 months previous screening.\n* IgE total concentration ranging from 30 to 1500 UI/ml.\n* Body weight between 20 to 150 kg Exclusion Criteria\n* Pregnant or lactating female or without safe and efficacious birth control method if of childbearing potential.\n* Currently smokers or history of smoking 10 or more packs per year.\n* Ex-smokers with a history of more than 10 years of smoking. As an exception, a participant with this criterion will be considered as eligible if the FEV1 reversibility of the first spirometry reaches 12%.\n* Active lung disease other than asthma.\n* Use of methotrexate, gold salts, troleandomycin, cyclosporine, immunosuppressants, gammaglobulin or any other type of monoclonal antibody used during the 6 months prior to the initial visit.\n* Use of omalizumab during the 4 months prior to de screening visit.\n* History of renal disease, cardiovascular disease, metabolic disease, hematologic disease, gastrointestinal disease, as well as immunodeficiency or cerebrovascular disease currently under treatment but not-controlled.\n* History of hepatic, neurologic, oncologic or autoimmune disease.\n* Participant under suspicion of having cancer.\n* Participants with history of hypersensitivity to sucrose, histidine, polysorbate 20 as well as to monoclonal antibodies or gammaglobulin.\n* Hypersensitivity to omalizumab or its excipients.\n* Abnormal values of the blood chemistry laboratory tests, over 2 times the upper limit normal, that are considered clinically significant.\n* Underage participant or any participant under vulnerable conditions who does not live with their parents or legal guardian.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "55 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Tuxtla Gutierrez", "state": "Chiapas", "zip": "29030", "country": "Mexico", "geoPoint": {"lat": 16.75973, "lon": -93.11308}}, {"facility": "Novartis Investigative Site", "city": "Mexico City", "state": "Distrito Federal", "zip": "14000", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Distrito Federal", "zip": "03020", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Distrito Federal", "zip": "03100", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Distrito Federal", "zip": "04700", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Distrito Federal", "zip": "04980", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Distrito Federal", "zip": "06090", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Distrito Federal", "zip": "06760", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Distrito Federal", "zip": "14050", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Mexico", "state": "Edo. De M\u00e9xico", "zip": "53910", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Novartis Investigative Site", "city": "Nezahualcoyotl", "state": "Estado De Mexico", "zip": "57730", "country": "Mexico", "geoPoint": {"lat": 19.40061, "lon": -99.01483}}, {"facility": "Novartis Investigative Site", "city": "Pachuca de Soto", "state": "Hidalgo", "zip": "42090", "country": "Mexico", "geoPoint": {"lat": 20.11697, "lon": -98.73329}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44500", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44600", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44620", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44690", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Novartis Investigative Site", "city": "Guadaljara", "state": "Jalisco", "zip": "44500", "country": "Mexico"}, {"facility": "Novartis Investigative Site", "city": "Tepic", "state": "Nayarit", "zip": "63000", "country": "Mexico", "geoPoint": {"lat": 21.50951, "lon": -104.89569}}, {"facility": "Novartis Investigative Site", "city": "Monterrey", "state": "Nuevo Le\u00f3n", "zip": "64020", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Novartis Investigative Site", "city": "Monterrey", "state": "Nuevo Le\u00f3n", "zip": "64718", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Novartis Investigative Site", "city": "M\u00e9rida", "state": "Yucat\u00e1n", "zip": "97070", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "FG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "FG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "FG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "40"}, {"groupId": "FG003", "numSubjects": "39"}]}, {"type": "Completed Study Treatment at Month 12", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "30"}, {"groupId": "FG003", "numSubjects": "27"}]}, {"type": "Discontinued Treatment Prior to Month 12", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "30"}, {"groupId": "FG003", "numSubjects": "27"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "12"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Other unspecified", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Informed consent withdrawn", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Non-compliance with lab inc/exclusion", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Withdrawal of study medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Missing", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The Intent-to-treat (ITT) population included participants who received at least one dose of study drug and had at least one post-baseline assessment of the primary or secondary efficacy variables.", "groups": [{"id": "BG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "BG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "BG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "BG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "39"}, {"groupId": "BG004", "value": "112"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.1", "spread": "3.32"}, {"groupId": "BG001", "value": "12.4", "spread": "1.80"}, {"groupId": "BG002", "value": "37.6", "spread": "10.01"}, {"groupId": "BG003", "value": "38.7", "spread": "10.30"}, {"groupId": "BG004", "value": "30.4", "spread": "14.84"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "70"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "42"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Mean Prescribed Budesonide Dose (\u03bcg) at Baseline", "description": "prescribed budesonide dose (in \u03bcg) at Baseline in intention to treat population and in intention to treat population", "populationDescription": "Pediatric and Adult intent-to-treat (ITT) and per protocol (PP) populations. ITT population received at least one dose of study drug and one post-baseline assessment of the primary/secondary efficacy variables. PP population was participants that completed 12 months of treatment, had a valid assessment of the primary efficacy variable at Week 24.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"title": "ITT", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "337.5", "spread": "95.74"}, {"groupId": "OG001", "value": "270.6", "spread": "98.52"}, {"groupId": "OG002", "value": "580.0", "spread": "201.53"}, {"groupId": "OG003", "value": "533.3", "spread": "248.50"}]}]}, {"title": "PP", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "363.6", "spread": "80.90"}, {"groupId": "OG001", "value": "250.0", "spread": "90.45"}, {"groupId": "OG002", "value": "575.0", "spread": "201.61"}, {"groupId": "OG003", "value": "533.3", "spread": "258.20"}]}]}]}, {"type": "SECONDARY", "title": "Number of Hospital Admissions Due to Asthma Exacerbation", "description": "A hospital admission is defined as admissions to hospital involving a stay of at least 24 hours.", "populationDescription": "Pediatric and Adult ITT population. ITT population received at least one dose of study drug and one post-baseline assessment of the primary/secondary efficacy variables.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "hospital admissions", "timeFrame": "12 month treatment duration", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Days Missed in School/Work Due to Asthma Exacerbation Episodes", "description": "Participants /parent/legal guarding reported number of missed days of school or work at each study visit via diaries.", "populationDescription": "Pediatric and Adult ITT population. ITT population received at least one dose of study drug and one post-baseline assessment of the primary/secondary efficacy variables.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "days", "timeFrame": "12 month treatment duration", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"title": "Missed school days", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "0"}]}]}, {"title": "Missed work days", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Control of Asthma Symptoms- Daytime Symptoms", "description": "The clinical control of asthma was defined according to the following criteria (GINA 2012): 1-Daytime symptoms: none or less than twice a week 2-Limitations of daily activities: none 3-Nocturnal symptoms or awakening because of asthma: none 4-Need of relief or rescue medication: none or less than twice a week 5-Lung function (PEF or FEV1) without administration of bronchodilator: normal", "populationDescription": "Pediatric and Adult ITT population. ITT population received at least one dose of study drug and one post-baseline assessment of the primary/secondary efficacy variables.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "12 month treatment duration", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62.5"}, {"groupId": "OG001", "value": "70.6"}, {"groupId": "OG002", "value": "82.5"}, {"groupId": "OG003", "value": "71.8"}]}]}]}, {"type": "SECONDARY", "title": "Control of Asthma Symptoms", "description": "The clinical control of asthma was defined according to the following criteria (GINA 2012): 1-Daytime symptoms: none or less than twice a week 2-Limitations of daily activities: none 3-Nocturnal symptoms or awakening because of asthma: none 4-Need of relief or rescue medication: none or less than twice a week 5-Lung function (PEF or FEV1) without administration of bronchodilator: normal", "populationDescription": "Pediatric and Adult ITT population. ITT population received at least one dose of study drug and one post-baseline assessment of the primary/secondary efficacy variables.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of days", "timeFrame": "12 month treatment duration", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"title": "Wheezing", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.4", "spread": "23.43"}, {"groupId": "OG001", "value": "21.1", "spread": "32.84"}, {"groupId": "OG002", "value": "25.4", "spread": "28.89"}, {"groupId": "OG003", "value": "29.0", "spread": "36.30"}]}]}, {"title": "Night time cough", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "33"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.8", "spread": "7.75"}, {"groupId": "OG001", "value": "20.8", "spread": "27.24"}, {"groupId": "OG002", "value": "20.6", "spread": "22.09"}, {"groupId": "OG003", "value": "32.3", "spread": "42.50"}]}]}]}, {"type": "SECONDARY", "title": "Control of Asthma Symptoms- Rescue Medication Use", "description": "The clinical control of asthma was defined according to the following criteria (GINA 2012): 1-Daytime symptoms: none or less than twice a week 2-Limitations of daily activities: none 3-Nocturnal symptoms or awakening because of asthma: none 4-Need of relief or rescue medication: none or less than twice a week 5-Lung function (PEF or FEV1) without administration of bronchodilator: normal", "populationDescription": "Pediatric and Adult ITT population. ITT population received at least one dose of study drug and one post-baseline assessment of the primary/secondary efficacy variables.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 month treatment duration", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "34"}, {"groupId": "OG003", "value": "33"}]}]}]}, {"type": "SECONDARY", "title": "Participants Requiring Oral Systemic Corticosteroids During the 12 Month Study Duration", "description": "Number of days of concomitant medications use reported by participants at all visits via diaries.", "populationDescription": "Number of patients requiring oral systemic corticosteroids within the ITT Pediatric and Adult population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of days", "timeFrame": "12 month treatment duration", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "5"}, {"groupId": "OG003", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.3", "spread": "4.62"}, {"groupId": "OG001", "value": "16.5", "spread": "19.09"}, {"groupId": "OG002", "value": "28.0", "spread": "35.67"}, {"groupId": "OG003", "value": "16.3", "spread": "17.35"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire (ACQ) at Baseline", "description": "The Asthma Control Questionnaire (ACQ) has six questions to be answered by the participants, each with a 7 point scale (0-good control, 6-poor control), and one question where the actual pre-bronchodilator Forced expiratory volume in 1 second (FEV1) value expressed in % of predicted FEV1 was classified to scores from 0 (\\> 95% of predicted) to 6 (\\< 50% of predicted). The overall score is the average of the 7 questions; a minimum overall score of 0 = good control of asthma whereas a maximum overall score of 6 = poor control of asthma.", "populationDescription": "Number of participants with a baseline measurement within the ITT Pediatric and Adult population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "1.31"}, {"groupId": "OG001", "value": "3.3", "spread": "1.26"}, {"groupId": "OG002", "value": "3.6", "spread": "1.09"}, {"groupId": "OG003", "value": "3.3", "spread": "1.35"}]}]}]}, {"type": "SECONDARY", "title": "Asthma Quality of Life Questionnaire (AQLQ) at Baseline", "description": "The quality of life will be measured by the standardized version of the Asthma Quality of Life Questionnaire (AQLQ\\[S\\]) score for adults and the pediatric version of the AQLQ(S) for pediatric participants (PAQLQ\\[S\\]) . The AQLQ(S) and PAQLQ(S0 contain 4 domains (activity limitations, symptoms, emotional function, and environmental stimuli), with a total of 32 items; each item is measured in a 7-point Likert scale of 1 to 7 (1 = severe impairment, 7 = no impairment). All items are weighted equally. Mean score is calculated across all items within each domain and the overall score is the mean score of the 32 items.", "populationDescription": "Number of participants with a baseline measurement within the ITT Pediatric and Adult population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device."}, {"id": "OG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device."}, {"id": "OG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device."}, {"id": "OG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "39"}]}], "classes": [{"title": "Overall", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "1.21"}, {"groupId": "OG001", "value": "3.4", "spread": "1.54"}, {"groupId": "OG002", "value": "2.9", "spread": "1.04"}, {"groupId": "OG003", "value": "3.4", "spread": "1.25"}]}]}, {"title": "Symptoms domain", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "1.49"}, {"groupId": "OG001", "value": "3.3", "spread": "1.48"}, {"groupId": "OG002", "value": "2.8", "spread": "1.16"}, {"groupId": "OG003", "value": "3.5", "spread": "1.37"}]}]}, {"title": "Activity limitations domain", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "1.18"}, {"groupId": "OG001", "value": "3.3", "spread": "1.47"}, {"groupId": "OG002", "value": "3.2", "spread": "1.07"}, {"groupId": "OG003", "value": "3.5", "spread": "1.25"}]}]}, {"title": "Emotional functions domain", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "1.47"}, {"groupId": "OG001", "value": "3.6", "spread": "1.76"}, {"groupId": "OG002", "value": "2.5", "spread": "1.16"}, {"groupId": "OG003", "value": "3.2", "spread": "1.49"}]}]}, {"title": "Environmental stimuli domain", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Environment domain is non-existent for pediatric population."}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Environment domain is non-existent for pediatric population."}, {"groupId": "OG002", "value": "2.7", "spread": "1.24"}, {"groupId": "OG003", "value": "3.1", "spread": "1.47"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 12 months.", "eventGroups": [{"id": "EG000", "title": "Pediatric Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received omalizumab injection for s.c. use 2 or 4 weeks according to the IgE level and body weight and budesonide + formoterol administered through an inhaler device.", "seriousNumAffected": 1, "seriousNumAtRisk": 16, "otherNumAffected": 11, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Pediatric Patients: Budesonide and Formoterol", "description": "Participants received budesonide + formoterol administered through an inhaler device.", "seriousNumAffected": 2, "seriousNumAtRisk": 17, "otherNumAffected": 7, "otherNumAtRisk": 17}, {"id": "EG002", "title": "Adult Patients: Omalizumab + Budesonide and Formoterol", "description": "Participants received Omalizumab every 2 or 4 weeks as a subcutaneous injection dose according to the IgE level and body weight. Participants also received and budesonide + formoterol administered through an inhaler device.", "seriousNumAffected": 2, "seriousNumAtRisk": 40, "otherNumAffected": 27, "otherNumAtRisk": 40}, {"id": "EG003", "title": "Adult Patients: Budesonide and Formoterol", "description": "Participants receive budesonide + formoterol administered through an inhaler device.", "seriousNumAffected": 1, "seriousNumAtRisk": 39, "otherNumAffected": 21, "otherNumAtRisk": 39}], "seriousEvents": [{"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Maternal exposure during pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Pelvic inflammatory disease", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Hepatic steatosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Expired product administered", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}], "otherEvents": [{"term": "Increased hunger", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Burning in the eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Conjuntivitis - bacterial", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Pruritus - ocular", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Abdominal pain -localized", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Colitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Epigastric pain - food-related", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Gastroenteritis - acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Gastroesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Hepatic steatosis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Pyelonephritis - acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Adynamia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Anxiety", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Fever", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Palpitations", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Tachycardia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Diarrhea - Acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "External Otitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Flu - common", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 39}]}, {"term": "flu-like symptoms", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 39}]}, {"term": "Influenza virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Pharyngitis - Acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Pharyngitis - bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Pharyngotonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 39}]}, {"term": "Rhinopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Sore throat", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Tonsillitis - acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Pruritus - injection site reaction", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Sea food allergy", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Hands tremor", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Lower Limb cramp", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 39}]}, {"term": "Muscle cramp", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Muscle pain - localized", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Pain - leg", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Pain - localized", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Tremor", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Head trauma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 39}]}, {"term": "Insomnia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Lipothymia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Allergic asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Cough - dry", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Cough - with sputum", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "CRUP syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Flu illness", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Nasal obstruction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Nose bleeding", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Odinofagia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Otorhinolaryngological examination", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Rhinitis - acute", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Rhinitis - allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Rhinorrhea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Rhinosinusitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Runny nose", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 39}]}, {"term": "Sneezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Sore throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 39}]}, {"term": "Sputum", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 39}]}, {"term": "Sputum increase", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 39}]}, {"term": "Erythema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}, {"term": "Pruritus - allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 39}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Clinical Disclosure Office", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}, {"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}]}}, "hasResults": true}